A multi-strategy investment firm focused on breakthrough biomedical technology and innovative healthcare companies worldwide
learn more
Our flagship private equity strategy invests in privately held breakthrough biomedical technology companies at all stages, from seed to crossover
Our structured opportunities strategy provides senior-secured financing to breakthrough biomedical technology companies
Our public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy investing in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data.
Our co-investment vehicles provide Catalio Limited Partners with direct access to our best deals